跳至主要内容
临床试验/NCT06450652
NCT06450652尚未招募不适用

Feasibility, Safety, and Effectiveness of Chinese Herbal Medicine for T2DM Patients With Comorbid Metabolic Syndrome: A Single-arm Pilot Study

Hong Kong Baptist University0 个研究点目标入组 15 人开始时间: 2024年6月最近更新:
适应症
干预措施
相关药物

试验速览

阶段
不适用
状态
尚未招募
入组人数
15
主要终点
Fasting plasma glucose (FPG)

研究概览

简要总结

This is a single-arm design. A total of 15 Type 2 Diabetes Mellitus (T2DM) patients with comorbid Metabolic Syndrome (MetS) will be recruited from community. The intervention will be a 4-week of Chinese Herbal Medicine granules treatment, which will consist of six Chinese herbs. The primary outcome measure will be fasting plasma glucose and blood pressure. Secondary outcome measures including changes of anthropometric data (body mass index, waist-to-hip ratio), lipid panels (total cholesterol, triglycerides, high-density lipoprotein, low-density lipoprotein), HbA1C, Framingham Stroke Risk Score (FSRS), Audit of diabetes-dependent quality of Life (ADDQoL), International Physical Activity Questionnaire Short Form (IPAQ-SF), daily step count and physiological parameters from wearable watch, dietary record, retinal and sublingual vein imaging, concurrent medications and adverse events.

研究设计

研究类型
Interventional
分配方式
Na
干预模型
Single Group
主要目的
Treatment
盲法
None

入排标准

年龄范围
30 Years 至 75 Years(Adult, Older Adult)
性别
All
接受健康志愿者

入选标准

  • Age between 30-75y.
  • Diagnosed with Type 2 diabetes no more than 5 years.
  • Having current prehypertension (systolic blood pressure 130-139 mmHg or diastolic blood pressure 85-89mmHg), or with a history of hypertension (systolic blood pressure 140-159mmHg or diastolic blood pressure 90-99mmHg).
  • Diagnosed with Metabolic Syndrome according to Guideline for the prevention and treatment of type 2 diabetes mellitus in China (2020 edition) from Chinese Diabetes Society. People who meet 3 of the following diagnostic criteria or more can be diagnosed as Metabolic Syndrome: (a)Abdominal obesity: waist circumference ≥ 90cm for male and ≥ 85cm for female; (b) Hyperglycemia: Fasting blood glucose ≥ 6.1mmol/L or 2-hour postprandial glucose ≥ 7.8mmol/L and/or those who have been diagnosed with hyperglycemia and in treatment; (c) Hypertension: blood pressure ≥ 130/85mmHg and/or those who have been diagnosed with hypertension and in treatment; (d) Fasting triglyceride ≥ 1.70mmol/L; (e) Fasting HDL-C < 1.04mmol/L.
  • Diagnosed with Accumulation of phlegm and dampness pattern or Intertwined phlegm and blood stasis pattern based on Traditional Chinese Medicine (TCM) theory.
  • Stable vital signs and with sufficient sensorimotor and language competency for completing assessments.

排除标准

  • Allergic history to Chinese herbal drugs or a known allergy to the ingredients of the CHM.
  • Diagnosed with type 1 diabetes, steroid-induced diabetes, gestational diabetes, or specific types of diabetes.
  • Diabetes accompanied by severe complications such as diabetic nephropathy, diabetic ketoacidosis, etc.
  • Secondary obesity (e.g., secondary to pituitary inflammation, tumor, etc.).
  • Secondary hypertension (e.g., pheochromocytoma, renal hypertension, etc.).
  • Secondary hyperlipidemia (e.g., hypothyroidism, nephrotic syndrome, etc.).
  • Experienced at least one day of diarrhea in the past 7 days.
  • With previous stroke history.
  • With unconsciousness, aphasia, and cognitive dysfunction.
  • With severe heart, liver, or kidney disease or bleeding disorders, or with other serious diseases (e.g. cancer, dementia, etc.).
  • Pregnancy or lactation female.
  • Had joined other clinical trial within past 4 weeks.

研究组 & 干预措施

Chinese Herbal Medicine granules

Experimental

干预措施: Chinese Herbal Medicine granules (Drug)

结局指标

主要结局

Fasting plasma glucose (FPG)

时间窗: Baseline, week 2, week 4, week 8.

FPG will be determined by taking a blood sample from participants who have fasted for 8-12 hours.

Blood pressure

时间窗: Baseline, week 2, week 4, week 8.

Blood pressure was measured thrice, after a 10 min rest, using a standard digital sphygmomanometer.

次要结局

  • Framingham Stroke Risk Score (FSRS)(Baseline, week 2, week 4, week 8.)
  • Physiological parameters and dietary records(Baseline, week 2, week 4, week 8.)
  • Audit of diabetes-dependent quality of Life (ADDQoL)(Baseline, week 4, week 8.)
  • International Physical Activity Questionnaire Short Form (IPAQ-SF)(Baseline, week 2, week 4, week 8.)
  • Anthropometric assessment, lipid panels, HbA1C(Baseline, week 2, week 4, week 8.)
  • Adverse events(Baseline, week 2, week 4, week 8.)

研究者

申办方类型
Other
责任方
Principal Investigator
主要研究者

ZhaoXiang Bian

Professor

Hong Kong Baptist University

相似试验